BIOVIE INC (BIVI)
US09074F2074 - Common Stock
BIOVIE INC
NASDAQ:BIVI (4/25/2024, 2:42:58 PM)
0.4901
-0.02 (-3.03%)
Company Profile
BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company is headquartered in Carson City, Nevada and currently employs 18 full-time employees. The company went IPO on 2014-01-14. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The firm is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.
Company Info
BIOVIE INC
680 W Nye Lane, Suite 201
Carson City NEVADA 90404
P: 17758883162
CEO: Cuong Do
Employees: 18
Website: https://www.bioviepharma.com/
BIVI News
Additionally, the Company announced approval of the non-proprietary name “bezisterim” for NE3107...
a month ago - Shareholders Foundation, Inc.Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation/PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in BioVie Inc. (NASDAQ: BIVI) shares. Investors,...
a month ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines - BIVI/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI) and certain...
a month ago - Faruqi & Faruqi LLPONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie
a month ago - NewMediaWireBIVI DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIVISearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
a month ago - TheNewswire.comBIVI DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIVIWHY: NEW YORK, NY - (NewMediaWire) - March 18, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and November 29, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
BIVI Twits
Here you can normally see the latest stock twits on BIVI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
